← Back to Search

Quetiapine Fumarate for Post-Traumatic Stress Disorder

Q: Is enrollment still open for this clinical trial?

According to the data published on clinicaltrials.gov, this study is not accepting new patients at the moment. Initially posted on February 1st 2019 and last updated April 29th 2022, the trial has ceased recruitment - though 744 other studies are still enrolling participants.

Q: Have any previous experiments utilized Quetiapine Fumarate?

Currently, there are 13 studies investigating Quetiapine Fumarate with 3 of them being in Phase 3. Researchers have established 419 locations to run these trials, the majority of which located in Bhubaneswar, Orissa.

Q: How many participants are being incorporated into this medical experiment?

This clinical trial is no longer actively seeking patients. Initially posted on February 1, 2019 and last edited April 29, 2022; however, there are currently 731 trials recruiting participants with Post Traumatic Stress Disorder (<a href="https://www.withpower.com/clinical-trials/ptsd">PTSD</a>) as well as 13 separate studies enrolling people for Quetiapine Fumarate treatment.

Q: To what ailments has Quetiapine Fumarate been prescribed?

Quetiapine Fumarate is a popular treatment for <a href="https://www.withpower.com/clinical-trials/anxiety">anxiety</a> disorders and other maladies such as acute coryza, mental <a href="https://www.withpower.com/clinical-trials/depression">depression</a>, and <a href="https://www.withpower.com/clinical-trials/bipolar-disorder">bipolar disorder</a>.

Q: Is this research the inaugural exploration of its kind?

Otsuka America Pharmaceutical launched their first Quetiapine Fumarate study in 2014, which enrolled 200 participants. After a successful Phase 4 drug approval process, there are now 13 separate clinical trials taking place across 138 cities and 27 countries.

Phase < 1

Waitlist Available

Led By Muhammad Baig, MD

Research Sponsored by The University of Texas Health Science Center at San Antonio

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1.5 yr

Awards & highlights

Study Summary

This trial is testing whether a drug called quetiapine is safe and effective for treating PTSD in veterans.

Eligible Conditions

Post Traumatic Stress Disorder

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1.5 yr

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1.5 yr

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1.5 yr for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage compliance in completing PE sessions

Side effects data

From 2009 Phase 4 trial • 376 Patients • NCT00672490

13%

Constipation

Weight Increased

Nausea

Tremor

Dizziness

Extrapyramidal Symptom

Upper respiratory tract infection

Liver function test abnormal

Vomiting

Somnolence

Diarrhoea

Hypersomnia

Hypothyroidism

Hyperlipidemia

Tachycardia

Fatigue

Dry mouth

Palpitations

Injury

100%

80%

60%

40%

20%

Study treatment Arm

Quetiapine Fumarate Used as Adjunct Therapy

Quetiapine Fumarate Used as Mono-Therapy

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: QuetiapineExperimental Treatment1 Intervention

Flexible dosing begins at 50 mg, titrating up to 100 mg at the end of week 2 with additional doses up to 400 mg per day if needed

Group II: Treatment As Usual (TAU)Active Control1 Intervention

Standard of care medications

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Quetiapine Fumarate

2011

Completed Phase 4

~1020

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor

452 Previous Clinical Trials

91,386 Total Patients Enrolled

South Central MIRECCUNKNOWN

Muhammad Baig, MDPrincipal InvestigatorSouth Texas Veterans Health Care System

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still open for this clinical trial?

"According to the data published on clinicaltrials.gov, this study is not accepting new patients at the moment. Initially posted on February 1st 2019 and last updated April 29th 2022, the trial has ceased recruitment - though 744 other studies are still enrolling participants."

Answered by AI

Have any previous experiments utilized Quetiapine Fumarate?

"Currently, there are 13 studies investigating Quetiapine Fumarate with 3 of them being in Phase 3. Researchers have established 419 locations to run these trials, the majority of which located in Bhubaneswar, Orissa."

Answered by AI

How many participants are being incorporated into this medical experiment?

"This clinical trial is no longer actively seeking patients. Initially posted on February 1, 2019 and last edited April 29, 2022; however, there are currently 731 trials recruiting participants with Post Traumatic Stress Disorder (PTSD) as well as 13 separate studies enrolling people for Quetiapine Fumarate treatment."

Answered by AI

To what ailments has Quetiapine Fumarate been prescribed?

"Quetiapine Fumarate is a popular treatment for anxiety disorders and other maladies such as acute coryza, mental depression, and bipolar disorder."

Answered by AI

Is this research the inaugural exploration of its kind?

"Otsuka America Pharmaceutical launched their first Quetiapine Fumarate study in 2014, which enrolled 200 participants. After a successful Phase 4 drug approval process, there are now 13 separate clinical trials taking place across 138 cities and 27 countries."

Answered by AI

Recent research and studies

Military Medical ResearchJournal

Quetiapine Augmentation of Prolonged Exposure Therapy in Veterans with PTSD and a History of Mild Traumatic Brain Injury: Design and Methodology of a Pilot Study

Baig, Muhammad R., Robert D. Beck, Jennifer L. Wilson, Jennifer A. Lemmer, Adeel Meraj, Eric C. Meyer, Jim Mintz, Alan L. Peterson, and John D. Roache. 2020. “Quetiapine Augmentation of Prolonged Exposure Therapy in Veterans with PTSD and a History of Mild Traumatic Brain Injury: Design and Methodology of a Pilot Study”. Military Medical Research. Springer Science and Business Media LLC. doi:10.1186/s40779-020-00278-0.

clinicaltrials.govStudy

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

2019. "Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04280965.